|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 564 active entries
50 Ronson Drive, Suite 105
Toronto, M9W 1B3
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Axela's automated platforms for multiplexed nucleic acid and protein analysis are specifically designed to simplify the transition from clinical discovery to diagnostic implementation. The company’s approach to biomarker analysis enables highly flexible, user-defined, multiplex panels for real-time or end-point measurements. This significantly improves the amount and quality of information derived when compared to traditional assays and provides access to unique categories of markers that form a pipeline of diagnostic offerings. Content development is focused in the areas of Oncology, Immune Status and near patient testing. Toronto based Axela develops research products for sale through life science distributors, and partners with diagnostic companies for clinical tests.
Last update of this entry: August 28, 2012